Bone Biologics Corp BBLG
are a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known
as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific
control over bone regeneration. The NELL-1 technology platform has been licensed exclusively for worldwide applications to us through
a technology transfer from the UCLA Technology Development Group on behalf of UC Regents ("UCLA TDG"). UCLA TDG and the Company
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $1.07B | $1.07B | — | — | — |
| R&D | $1.1M | $2.1M | $6.9M | $1.6M | $82.0K | $340.7K | $1.1M | $104.5K | $1.4M | $10.2M |
| SG&A | $2.2M | $2.1M | $2.5M | $2.1M | $1.0M | $484.3K | $1.4M | $2.7M | $4.0M | $5.7M |
| Total operating expenses | $3.2M | $4.2M | $9.4M | $3.7M | $1.1M | $825.0K | $2.4M | $2.8M | $2.6M | $20.4M |
| Operating income | -$3.2M | -$4.2M | -$9.4M | -$3.7M | -$1.1M | -$825.0K | -$2.4M | -$2.8M | -$2.6M | -$20.4M |
| Interest expense | — | — | $1.9K | — | — | — | — | — | — | — |
| Pre-tax income | — | — | — | — | -$1.6M | -$1.8M | -$3.4M | -$4.4M | -$7.0M | -$25.9M |
| Income tax | — | — | — | — | $1.6K | $1.6K | $1.6K | $1.7K | $1.6K | $2.2K |
| Net income | -$3.1M | -$4.1M | -$8.9M | -$1.5M | -$1.6M | -$1.8M | -$3.4M | -$4.4M | -$7.1M | -$25.9M |
| EPS, basic | -2.65 | -28.96 | -34.01 | -31.15 | -0.35 | — | — | — | — | — |
| EPS, diluted | -2.65 | -28.96 | -34.01 | -31.15 | -0.35 | -0.63 | -0.47 | -0.88 | -1.81 | -0.69 |
| Shares, diluted (wtd. avg.) | 1.2M | 252,960 | 263,137 | 47,658 | — | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | — | — | — | — | $6.7M | — | $24.1K | $955.4K | $690.3K | $620.4K |
| Total current assets | $5.8M | $3.9M | $3.7M | $8.5M | — | — | $30.8K | $1.0M | $795.5K | $2.3M |
| Property, plant and equipment | — | — | — | — | — | — | — | $50 | $146 | $322 |
| Total assets | $5.8M | $3.9M | $3.7M | $8.5M | $6.7M | $0 | $30.8K | $1.0M | $795.7K | $2.3M |
| Accounts payable | $417.9K | $373.0K | $360.7K | $104.8K | $99.9K | $465.4K | $42.9K | $125.2K | $216.9K | $226.5K |
| Total current liabilities | $418.6K | $377.7K | $831.4K | $2.5M | $99.9K | $13.7M | $578.4K | $9.6M | $961.8K | $481.7K |
| Total liabilities | $418.6K | $377.7K | $831.4K | $2.5M | $99.9K | $13.7M | $11.9M | $9.6M | $9.2M | $7.7M |
| Retained earnings | -$88.1M | -$85.0M | -$80.9M | -$72.0M | -$70.5M | -$68.9M | -$67.0M | -$63.6M | -$59.2M | $43.2M |
| Total equity | $5.4M | $3.5M | $2.9M | $5.9M | $6.6M | -$13.7M | -$11.9M | -$8.6M | -$8.4M | -$8.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.7M | -$4.1M | -$9.6M | -$3.6M | -$1.2M | -$426.9K | -$3.3M | -$4.1M | -$3.3M | -$7.3M |
| Depreciation and amortisation | — | — | — | — | — | — | $50 | $96 | $96 | $700 |
| Stock-based compensation | $256.4K | $188.8K | $152.6K | $266.6K | $207.0K | — | $49.7K | $516.6K | $1.6M | $4.1M |
| Financing cash flow | $4.7M | $4.4M | $5.0M | $4.4M | $7.9M | $402.8K | $2.3M | $4.4M | $3.4M | $6.8M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-040640.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $1.07B | $1.07B | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$25.9M | -$7.1M | -$4.4M | -$3.4M | -$1.8M | -$1.6M | -$1.5M | -$8.9M | -$4.1M | -$3.1M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event Item 8.01
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
- Material agreement signed Item 1.01
- Other event Item 8.01
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3842
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | $159.78B | 57.5x | 20.5% |
| EW | Edwards Lifesciences Corp | $51.34B | 48.7x | 11.5% |
| STE | STERIS plc | $22.63B | 29.3x | 8.7% |
| ZBH | ZIMMER BIOMET HOLDINGS, INC. | $18.80B | 27.8x | 7.2% |
| ALGN | ALIGN TECHNOLOGY INC | $10.98B | 27.3x | 0.9% |
| MSA | MSA Safety Inc | $7.03B | 25.7x | 3.7% |
| ESTA | ESTABLISHMENT LABS HOLDINGS INC. | $1.90B | — | 27.1% |
| CDRE | Cadre Holdings, Inc. | $1.28B | 29.4x | 7.5% |